Biologics Licence Application

August 14, 2018

First Patient Dosed in Phase 2 Trial of ADCT-402 in DLBCL

News

ADC Therapeutics has dosed the first participant in its Phase 2 trial assessing ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The trial is expected to support the ... Read more

August 18, 2017

Adcetris Might Be Approved for CTCL by December, as FDA Reviews Marketing Application

News

The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) required to bring Seattle Genetics’ Adcetris (brentuximab vedotin) to the market for the treatment ... Read more

May 30, 2017

FDA to Review Kite’s Application for CAR T-Cell Therapy to Treat Aggressive Non-Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration (FDA) has accepted for review the biologics license application (BLA) seeking the approval of axicabtagene ciloleucel (KTE-C19) for the treatment of refractory aggressive non-Hodgkin’s ... Read more